Compare MATH & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MATH | COEP |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.8M | 100.4M |
| IPO Year | N/A | N/A |
| Metric | MATH | COEP |
|---|---|---|
| Price | $1.95 | $14.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 48.0K | ★ 52.2K |
| Earning Date | 03-06-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $44,567,257.00 | $500,996.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.95 | ★ N/A |
| Revenue Growth | ★ 165.86 | N/A |
| 52 Week Low | $1.25 | $6.26 |
| 52 Week High | $4.17 | $21.41 |
| Indicator | MATH | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 36.11 | 49.48 |
| Support Level | $1.90 | $13.25 |
| Resistance Level | $2.09 | $14.30 |
| Average True Range (ATR) | 0.13 | 1.09 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 9.62 | 60.34 |
Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.